Background
Inhaled drug delivery is the foundation of chronic obstructive pulmonary disease (COPD) pharmacological treatment [
1]. The most common devices used to administer aerosolized medication in day-to-day respiratory practice are the pressurized metered-dose inhaler (MDIs) and dry powder inhaler (DPIs) [
2]. The ability to use these inhalers adequately may become problematic among patients with COPD whose disease and symptoms become more severe. For pressurized MDIs, patients need to inhale correctly and coordinate breathing and actuation to ensure effective drug delivery. For DPIs, patients may struggle to generate sufficient inspiratory capacity to overcome the internal resistance of the device to de-aggregate the powdered drug into fine particles small enough for lung deposition [
2,
3].
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report recognize that markers (eg, symptoms and exacerbations), other than lung function impairment are associated with more severe disease [
1]. Nebulized therapy may be an option in patients with more severe markers of COPD. Nebulized bronchodilators are recommended for patients with COPD who have very low inspiratory flow rates, physical, or mental impairments that preclude the use of inhalers, including elderly patients and patients with severe disease. They are also available to patients with COPD who prefer nebulized therapies [
2,
4,
5].
Revefenacin inhalation solution is a once-daily long-acting muscarinic antagonist delivered by a standard jet nebulizer that is approved by the US Food and Drug Administration (FDA) for the maintenance treatment of patients with COPD [
6]. The efficacy of revefenacin has been demonstrated in previous randomized, controlled, phase 3 trials in broad populations of patients with moderate to very severe COPD with or without concurrent long-acting ß agonist (LABA). Revefenacin significantly improved lung function (trough forced expiratory volume in 1 s [FEV
1] and overall treatment effect FEV
1) compared with placebo in two replicate 12-week studies [
7]. Revefenacin treatment was shown to improve FEV
1 and respiratory health outcomes in a 52-week study with results similar to tiotropium via HandiHaler® [
8]. Revefenacin was well tolerated for 52 weeks and has a safety profile that supports its long-term use in patients with COPD [
9]. In addition, revefenacin was not associated with adverse cardiovascular events [
10,
11]. Therefore, it may provide a beneficial treatment option for patients with cardiovascular disease, one of the most common comorbidities among patients with COPD [
12].
Identifying patient subgroups who are most likely to benefit from nebulized long-acting muscarinic antagonist (LAMA) treatment can help clinicians direct therapy to patients at high risk for COPD exacerbations. Here, in this post hoc subgroup analysis, we evaluated the efficacy, and health outcomes of revefenacin 175 μg versus placebo, in patients with markers of more severe COPD who participated in the replicate, placebo-controlled, 12-week phase 3 trials (0126 and 0127). Some of the methods and results of this analysis were previously reported in the form of an abstract [
13].
Discussion
This post hoc subgroup analysis of two replicate, randomized, double-blind, placebo-controlled, parallel-group, 12-week phase 3 trials (0126 and 0127) provides evidence for the efficacy of revefenacin delivered by a standard jet nebulizer in patients with COPD that had markers of severe disease. This analysis of pooled data from Studies 0126 and 0127 in all subgroups of patients with COPD that had markers of severe disease, showed that revefenacin was associated with significant improvements in lung function (range, 102–176 mL), which was comparable with the ITT population (148 mL).
In addition, revefenacin demonstrated improvements in health-related quality of life (as measured by SGRQ responders) and dyspnea (as measured by TDI responders) in the majority of patient subgroups versus placebo; these improvements were also comparable to those observed in the ITT population. The odds of being a SGRQ responder were significantly greater among patients with severe airflow obstruction (percent predicted FEV1 30%–< 50%), very severe airflow obstruction (percent predicted FEV1 < 30%), and those classified as 2011 GOLD D. Among patients with comorbidities, the odds of response in the revefenacin group with a history of cardiovascular disease showed a non-significant trend (odds ratio > 2.0) compared with placebo. It is likely significance was not met due to the relatively small patient numbers. The odds of being a TDI responder were significantly greater among patients with severe airflow obstruction (percent predicted FEV1 30%–< 50%), and those aged > 75 years, and there was a tendency towards significance in the 2011 GOLD D subgroup.
Results of this analysis are consistent with other studies that evaluated the efficacy of patients taking revefenacin and a concomitant LABA or LABA/ICS, or combining other LAMAs with LABA or LABA/ICS. Revefenacin 175 μg demonstrated improvements in FEV
1 in concomitant LABA patients in a 52 week study [
8]. The efficacy of combined LAMA/LABA treatments has been shown to improve lung function and health outcomes [
18‐
20]. In a systematic review and meta-analysis, it was reported that combining LAMA with LABA and ICS in patients with advanced COPD have better lung function and health-related quality of life and lower rates of moderate/severe COPD exacerbations than dual therapy or monotherapy [
21].
In this analysis, revefenacin resulted in significant improvements in lung function, SGRQ and TDI among patients with severe airflow obstruction (percent predicted FEV
1 30%–< 50%) and classified as GOLD D in this study, which is consistent with previous studies. Nebulized glycopyrrolate was shown to improve FEV
1, SGRQ, and TDI in patients with moderate to very severe COPD [
22]. Furthermore, tiotropium demonstrated higher efficacy versus salmeterol in prolonging time to first COPD exacerbation and reducing number of exacerbations in patients both at high exacerbation risk [
18]. In addition, aclidinium 400 μg significantly improved respiratory symptoms among patients who were classified as GOLD D at baseline [
23].
Patients with COPD frequently have comorbid conditions, which can influence mortality and hospitalizations [
1]. In this study, revefenacin demonstrated significant improvements in FEV
1 and health outcomes among patient subgroups with cardiovascular disease, and diabetes mellitus compared with patients who received placebo. Similarly, nebulized glycopyrrolate improved FEV
1, and patient-reported outcomes in patients with COPD, irrespective of cardiovascular risk status [
24]. In previous studies of patients with COPD and comorbid type 2 diabetes, ICS therapy may have a negative impact on diabetes control, and patients prescribed higher doses may be at greater risk of diabetes progression [
25,
26]. In the GOLD report, combination ICS/LABA or LAMA/LABA or LAMA monotherapy are recommended for GOLD D patients [
1]. However, in patients with comorbid diabetes, it may be more appropriate to limit the use of ICS to the minority of patients with COPD who might benefit.
There were no safety issues identified with the use of revefenacin in patients with cardiac risk factors [
7,
9]. In a preclinical study, revefenacin was shown to be a high-affinity competitive antagonist at human recombinant muscarinic acetylcholine receptors with kinetic functional selectivity for M
3 over M
2 muscarinic acetylcholine receptors [
27]. In addition, revefenacin is a metabolically labile primary amide “soft-drug” site that allows rapid systemic clearance of the parent drug, thus potentially minimizing systemically mediated adverse events [
27,
28].
Results of this analysis also demonstrated significant improvements in FEV
1 in patients who received revefenacin among subgroups aged > 65 years and > 75 years, and cognitive/mental impairments, versus those who received placebo. Similarly, a retrospective analysis demonstrated the efficacy and safety of tiotropium among elderly patients with COPD (< 70 years, 70–79 years, and ≥ 80 years) [
29]. Previous studies have suggested that nebulized therapy may be an appropriate option in patients with COPD and arthritis, impaired manual dexterity, chronic muscle weakness, or mental health or confusion disorders, or who are in hospitals, tertiary care centers, and assisted care settings as they may prefer nebulized therapy that is easy to use and does not require special training [
2,
30].
Several limitations should be noted for this study. The treatment period was only three months, which does not allow for conclusions on long-term treatment. Due to small sample sizes in the subgroups and post hoc nature of this study, results should be interpreted with caution. The populations assessed in this study had stable COPD and did not include patients that had recent hospitalizations or respiratory infections. Peak inspiratory flow rate was not assessed at baseline, and therefore, patients with a suboptimal peak inspiratory flow rate could not be assessed as a potential population with markers of more severe COPD.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.